RNS Number : 3183W Renalytix AI PLC 22 April 2021 Price Monitoring Extension The auction call period has been extended in this security by 5 minutes. Auction call extensions give London Stock Exchange electronic order book users a further opportunity to review the prices and sizes of orders
RNS Number : 2366W Renalytix AI PLC 22 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") U.S. General Services Administration Grants 10-Year Governmentwide Contract for RenalytixAI KidneyIntelX Testing KidneyIntelX Testing Services Available to 140 U.S.
RNS Number : 9600V Renalytix AI PLC 20 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") KidneyIntelX Demonstrates Performance and Informs Treatment Decisions in Multinational CANagliflozin CardioVAScular Assessment Study (CANVAS) Data from 1,325 CANVAS Participants with
RNS Number : 8100V Renalytix AI PLC 19 April 2021 Renalytix AI plc Director/PDMR Shareholding New York , 19 April 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence -enabled in vitro diagnostics company, focused on optimizing
RNS Number : 3696V Renalytix AI PLC 14 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") RenalytixAI and Joslin Diabetes Center Build on Proprietary Kidney Biomarker Portfolio for KidneyIntelX Platform Agreement provides RenalytixAI with exclusive option to access
RNS Number : 7571U Renalytix AI PLC 08 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Clinical Utility Study Demonstrates Primary Care Physicians Highly Likely to Order KidneyIntelX to Inform Care Decisions Value of KidneyIntelX Testing Demonstrated by Data from 401
RNS Number : 4091U Renalytix AI PLC 06 April 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Multi-Center Study Finds KidneyIntelX 72% More Effective Than Current Standard of Care In Identifying Early-Stage Patients at High Risk for Kidney Disease Progression and Failure
RNS Number : 1874S Renalytix AI PLC 15 March 2021 Renalytix AI plc (" RenalytixAI " or the " Company ") Update on Finalization of MCIT Rule to Provide National Medicare Coverage for FDA Breakthrough Devices and Diagnostics NEW YORK , March 15, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ:
RNS Number : 2460R Renalytix AI PLC 04 March 2021 Renalytix AI plc ("RenalytixAI", the "Company" or the "Group") Issue of shares under the 2020 Employee Share Purchase Plan, PDMR Dealing and Total Voting Rights New York , 4 March 2021 - Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX),, an
RNS Number : 8363Q Renalytix AI PLC 02 March 2021 RenalytixAI Reports Financial Results for Second Quarter of Fiscal Year 2021 NEW YORK , March 2, 2021 - Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) ("RenalytixAI" or the "Company"), an artificial intelligence-enabled in vitro diagnostics